Overview

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Dose escalation phase 1 study of PARP inhibitor PF-01367338 in combination with chemotherapy in adult patients with advanced solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Clovis Oncology, Inc.
Treatments:
Carboplatin
Poly(ADP-ribose) Polymerase Inhibitors
Rucaparib